A phase 2 study of ONC201 in recurrent/refractory metastatic breast cancer and advanced endometrial carcinoma

被引：0
|
作者：
Gatti-Mays, Margaret E.
Greer, Yoshimi
Steinberg, Seth
Soltani, Sanaz
Collins, Julie
Olson, Michelle
Ojemuyiwa, Michelle
Annunziata, Christina
Lee, Jung-Min
Nunes, Ana
Lipkowitz, Stan
Zimmer, Alexandra
机构：
[1] NCI, Womens Malignancies Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, NIH, Bethesda, MD 20892 USA
[3] Walter Reed Natl Mil Med Ctr, Murtha Canc Ctr, Bethesda, MD USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-07-04
引用
收藏
页数：1
相关论文
共 50 条
  • [11] ONC201 has anti-tumorigenic effects in obesity-driven endometrial cancer
    Tucker, K.
    Staley, A.
    Pierce, S. R.
    Fan, Y.
    Yin, Y.
    Sun, W.
    Zhao, X.
    Zhang, Y.
    Lee, D.
    Prabhu, V.
    Zhou, C.
    Bae-Jump, V. L.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 49 - 49
  • [12] Imipridone (ONC201) and Radiation Therapy Combination Shows Promise in Breast Cancer Treatment
    Jhawar, S. R.
    Thandoni, A.
    Goyal, S.
    Wang, S. J.
    Wu, H.
    Hassan, S.
    Schiff, D. S.
    Allen, J.
    Stogniew, M.
    Tarapore, R.
    Bertino, J.
    Haffty, B. G., Jr.
    Zloza, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E180 - E181
  • [13] Anti-tumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo
    Ray, J.
    Ralff, M.
    Jhaveri, A.
    El-Deiry, W.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 76 - 77
  • [14] Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma
    Humber, C.
    Tierney, J.
    Symonds, P.
    Collingwood, M.
    Kirwan, J.
    Williams, C.
    Green, J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (04):
  • [15] Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma
    Humber, C
    Tierney, J
    Symonds, P
    Collingwood, M
    Kirwan, J
    Williams, C
    Green, J
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (03):
  • [16] Phase 2 study of DRD2 antagonist/ClpP agonist ONC201 in neuroendocrine tumors.
    Anderson, Peter Meade
    Gortz, Janette
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [17] Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma
    Vale, Claire L.
    Tierney, Jayne
    Bull, Sarah J.
    Symonds, Paul R.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (08):
  • [18] A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma
    Arrillaga-Romany, Isabel
    Chi, Andrew S.
    Allen, Joshua E.
    Oster, Wolfgang
    Wen, Patrick Y.
    Batchelor, Tracy T.
    ONCOTARGET, 2017, 8 (45) : 79298 - 79304
  • [19] A phase II study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer
    Oaknin, A.
    Rubio Perez, M. J.
    Farinas Madrid, L.
    Redondo, A.
    Yubero Esteban, A.
    Gil Martin, M.
    Gonzalez Martin, A.
    Romero, I.
    Garcia-Donas, J.
    Serrano, R.
    Gallego Martinez, A.
    Ocariz Diez, M.
    Sanchez Lorenzo, M. L.
    Lopez Olmedo, M. D. Fenor De La Maza
    Rodriguez Freixinos, V.
    Piulats Rodriguez, J. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [20] ONC201 demonstrates anti-tumorigenic and anti-metastatic activity in uterine serous carcinoma in vitro
    Fang, Ziwei
    Wang, Jiandong
    Clark, Leslie H.
    Sun, Wenchuan
    Yin, Yajie
    Kong, Weimin
    Pierce, Stuart R.
    West, Lindsay
    Sullivan, Stephanie A.
    Tran, Arthur-Quan
    Prabhu, Varun V.
    Zhou, Chunxiao
    Bae-Jump, Victoria
    AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 8 (08): : 1551 - 1563
12345